Key result
BEYOND trial evaluates SGLT-2 inhibitors vs other glucose-lowering drugs to reduce AF recurrence in diabetes.
Why the study?
Given the close association between AF, heart failure, and DM, it was hypothesized that SGLT-2 inhibitors provide therapeutic benefits for AF rhythm control in patients with diabetes.
Do SGLT-2 inhibitors reduce the recurrence of atrial fibrillation in patients newly diagnosed with AF and diabetes mellitus?
RCT (n=716)
Open-label, blinded endpoint (PROBE)
1:1
Yes
Do SGLT-2 inhibitors reduce the recurrence of atrial fibrillation in patients newly diagnosed with AF and diabetes mellitus?
Answers are grounded in this paper and cite their sources.
The BEYOND trial protocol outlines a randomized study to determine if SGLT-2 inhibitors improve rhythm control and reduce atrial fibrillation recurrence in patients with newly diagnosed AF and diabetes.
SGLT-2 inhibitor, traditionally used for glycemic control, has several beneficial effects that can help manage heart failure (HF). SGLT-2 inhibitors reduce the risk of cardiovascular mortality in patients with HF. As atrial fibrillation (AF) is closely associated with HF and diabetes mellitus (DM) is a risk factor for AF, we assume that SGLT-2 inhibitors will also show therapeutic benefits regarding AF, especially for rhythm control. This trial has a multicenter, prospective, open, blinded endpoint design. It is a 1:1 randomized and controlled study. A total of 716 patients who are newly diagnosed of AF and DM within 1 year will be enrolled from 7 tertiary medical centers. The trial is designed to compare the effects of SGLT-2 inhibitors and other oral hypoglycemic agents on atrial rhythm control in patients with AF and DM. The primary outcome is the recurrence of AF within a year (including post-antiarrhythmic drugs (AAD) or ablation). The secondary outcomes are the ablation rate within a year, change in AF burden, size of the left atrium, NT-proBNP, the AF symptom score, and the quality of life. This trial will prospectively evaluate the effect and safety of SGLT-2 inhibitors on AF rhythm control in patients with DM. It will provide an invaluable dataset on rhythm control in AF with DM for future studies and offer novel information to assist in clinical decisions. (BEYOND trial, ClinicalTrials.gov number: NCT05029115. https://clinicaltrials.gov/ct2/show/NCT05029115).
No takes yet. Share an insight, caveat, or question.
Lee et al. (2023) conducted an RCT in Atrial fibrillation and diabetes mellitus (n=716). SGLT-2 inhibitors vs. Other oral hypoglycemic agents was evaluated on Recurrence of atrial fibrillation within a year (including post-antiarrhythmic drugs or ablation). SGLT-2 inhibitors will be evaluated for their efficacy in reducing atrial fibrillation recurrence compared to other oral hypoglycemic agents in 716 patients with diabetes in the planned BEYOND trial.
Synapse has enriched 10 related papers. Consider them for comparative context: